These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 11911803)

  • 1. Neutralizing and binding antibodies to IFN-beta: relative frequency in relapsing-remitting multiple sclerosis patients treated with different IFN-beta preparations.
    Scagnolari C; Bellomi F; Turriziani O; Bagnato F; Tomassini V; Lavolpe V; Ruggieri M; Bruschi F; Meucci G; Dicuonzo G; Antonelli G
    J Interferon Cytokine Res; 2002 Feb; 22(2):207-13. PubMed ID: 11911803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
    Hegen H; Millonig A; Bertolotto A; Comabella M; Giovanonni G; Guger M; Hoelzl M; Khalil M; Killestein J; Lindberg R; Malucchi S; Mehling M; Montalban X; Polman CH; Rudzki D; Schautzer F; Sellebjerg F; Sørensen PS; Deisenhammer F
    Mult Scler; 2014 Apr; 20(5):577-87. PubMed ID: 24009164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discordant effect of IFN-beta1a therapy on anti-IFN antibodies and thyroid disease development in patients with multiple sclerosis.
    Monzani F; Meucci G; Caraccio N; Saviozzi M; Casolaro A; Moscato G; Lombardo F; Mosti S; Scagnolari C; Bruschi F; Antonelli G; Ferrannini E; Murri L
    J Interferon Cytokine Res; 2002 Jul; 22(7):773-81. PubMed ID: 12184915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reduced effectiveness of long-term interferon-beta treatment on relapses in neutralizing antibody-positive multiple sclerosis patients: a Canadian multiple sclerosis clinic-based study.
    Boz C; Oger J; Gibbs E; Grossberg SE;
    Mult Scler; 2007 Nov; 13(9):1127-37. PubMed ID: 17967840
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Development of binding antibodies to interferon-beta during treatment of multiple sclerosis with different types of interferon-beta].
    Bartosik-Psujek H; Mitosek-Szewczyk K; Belniak E; Stelmasiak Z
    Pol Merkur Lekarski; 2004 Jul; 17(97):28-32. PubMed ID: 15559606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
    Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies against interferon-beta in multiple sclerosis.
    Aarskog NK; Marøy T; Myhr KM; Vedeler CA
    J Neuroimmunol; 2009 Jul; 212(1-2):148-50. PubMed ID: 19467718
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cross-reactivity of binding antibodies with different interferon beta formulations used as disease-modifying drugs in multiple sclerosis patients.
    Wencel-Warot A; Michalak S; Warot M; Kalinowska-Lyszczarz A; Kazmierski R
    Medicine (Baltimore); 2016 Nov; 95(45):e5337. PubMed ID: 27828855
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The assessment of development of binding antibodies to interferon beta during interferon beta 1a treatment of multiple sclerosis].
    Bartosik-Psujek H; Belniak E; Mitosek-Szewczyk K; Rejdak K; Dobosz B; Stelmasiak Z
    Neurol Neurochir Pol; 2003; 37(4):799-809. PubMed ID: 14746240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comparison of the biologic activity of two recombinant IFN-beta preparations used in the treatment of relapsing-remitting multiple sclerosis.
    Antonetti F; Finocchiaro O; Mascia M; Terlizzese MG; Jaber A
    J Interferon Cytokine Res; 2002 Dec; 22(12):1181-4. PubMed ID: 12581490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon-beta (INF-beta) antibodies in interferon-beta1a- and interferon-beta1b-treated multiple sclerosis patients. Prevalence, kinetics, cross-reactivity, and factors enhancing interferon-beta immunogenicity in vivo.
    Perini P; Facchinetti A; Bulian P; Massaro AR; Pascalis DD; Bertolotto A; Biasi G; Gallo P
    Eur Cytokine Netw; 2001 Mar; 12(1):56-61. PubMed ID: 11282547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow up study in an independent laboratory.
    Bertolotto A; Malucchi S; Sala A; Orefice G; Carrieri PB; Capobianco M; Milano E; Melis F; Giordana MT
    J Neurol Neurosurg Psychiatry; 2002 Aug; 73(2):148-53. PubMed ID: 12122172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and characterization of a non-cell-based assay to assess the presence of neutralizing antibodies to interferon-beta in clinical samples.
    Cludts I; Meager A; Thorpe R; Wadhwa M
    J Immunol Methods; 2013 Sep; 395(1-2):37-44. PubMed ID: 23831137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients.
    Gneiss C; Tripp P; Reichartseder F; Egg R; Ehling R; Lutterotti A; Khalil M; Kuenz B; Mayringer I; Reindl M; Berger T; Deisenhammer F
    Mult Scler; 2006 Dec; 12(6):731-7. PubMed ID: 17263000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenic effects of recombinant interferon-beta therapy disrupt the JAK/STAT pathway in primary immune cells from patients with multiple sclerosis.
    Gavasso S; Gjertsen B; Anderssen E; Myhr K; Vedeler C
    Mult Scler; 2012 Aug; 18(8):1116-24. PubMed ID: 22287540
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serial immunoprecipitation assays for interferon--(IFN)-beta antibodies in multiple sclerosis patients.
    Lampasona V; Rio J; Franciotta D; Furlan R; Avolio C; Fazio R; Lavolpe V; Vincent A; Comi G; Trojano M; Montalban X; Martino G
    Eur Cytokine Netw; 2003; 14(3):154-7. PubMed ID: 14656689
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A case study on the effect of neutralizing antibodies to interferon beta 1b in multiple sclerosis patients followed for 3 years with monthly imaging.
    Chiu AW; Ehrmantraut M; Richert ND; Ikonomidou VN; Pellegrini S; McFarland HF; Frank JA; Bagnato F
    Clin Exp Immunol; 2007 Oct; 150(1):61-7. PubMed ID: 17666095
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neutralizing antibody production against Rebif® and ReciGen® in Relapsing-Remitting Multiple Sclerosis (RRMS) patients and its association with patient's disability.
    Shokrollahi Barough M; Ashtari F; Sadat Akhavi M; Asghari N; Mosayebi G; Mirmohammadkhani M; Kokhaei N; Bahraminia F; Ajami A; Kokhaei P
    Int Immunopharmacol; 2018 Sep; 62():109-113. PubMed ID: 29990690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neutralizing and binding anti-interferon-beta (IFN-beta) antibodies. A comparison between IFN-beta-1a and IFN-beta-1b treatment in multiple sclerosis.
    Kivisäkk P; Alm GV; Fredrikson S; Link H
    Eur J Neurol; 2000 Jan; 7(1):27-34. PubMed ID: 10809912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neutralizing anti-interferon beta antibodies are associated with reduced side effects and delayed impact on efficacy of Interferon-beta.
    Farrell R; Kapoor R; Leary S; Rudge P; Thompson A; Miller D; Giovannoni G
    Mult Scler; 2008 Mar; 14(2):212-8. PubMed ID: 17986510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.